Loading data for BFRI — first visit, this takes a few seconds.

알림

Biofrontera Inc. (BFRI)

NasdaqCM: BFRI · 실시간 가격 · USD

1.30

+0.04 (3.17%)

종가 기준: Aug 19, 2026, 5:43 PM

3.17% (1D)

데이터 없음

매수호가	0.98
시가총액	21.39M
매출 (ttm)	46.17M
순이익 (ttm)	-6.37M
베타	n/a
EPS (ttm)	-0.43
P/E (ttm)	n/a
선행 P/E	4.5
P/B (ttm)	3.44
P/S (ttm)	0.46
Earnings Date	Aug 13, 2026

매도호가	1.61
거래량	976,249
평균 거래량 (20일)	325,403
시가	1.28
전일 종가	1.26
일중 범위	1.26 - 1.40
52주 범위	0.56 - 1.40
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

BFRI 소개

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts....

섹터 Healthcare

IPO 일자 Oct 29, 2021

직원 수 84

상장 거래소 NasdaqCM

티커 BFRI

웹사이트 https://www.biofrontera-us.com

전체 기업 정보

재무 실적

2025년 Biofrontera의 매출은 41.7M로, 전년 37.32M 대비 11.75% 증가했습니다. 순이익은 -10.54M로, -40.67% 감소했습니다.

재무제표

어닝 서프라이즈

Biofrontera가 May 14, 2026에 분기 실적을 발표했습니다:

매출 $10.08M 예상치 하회 $0, 및 17.42% 전년 대비 성장.

EPS -0.41 예상치 하회 -0.36, 및 19.61% 전년 대비 성장.

다음 실적 발표

Biofrontera Inc.의 실적 발표 예정일은 Aug 13, 2026, 장 마감 후입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

6일 전 · Zacks

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of +70.59% and +33.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

6일 전 · Zacks

BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates

BioStem Technologies, Inc. (BSEM) delivered earnings and revenue surprises of -4.00% and +23.43%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the st...

1주 전 · Zacks

Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates

Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

1주 전 · Zacks

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2주 전 · Zacks

Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of +26.32% and +16.42%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 페이지 중 1

Biofrontera Inc. (BFRI)